Lepton PharmaceuticalsLepton Pharmaceuticals
 
Lepton PharmaceuticalsLepton Pharmaceuticals
  • Home
  • About Us
    • About Us
    • Board of directors
    • Team
  • Our Products
    • Pipeline
    • LN-Cast-01
    • LN-008 si-MASP2
  • Our Science
    • miRNA based Castling
    • siRNA and miRNA
    • Non-coding RNA
    • siRNA Advantages
  • Contact Us
  • News

Recent Posts

  • May 30, 2024LEPTON Pharmaceuticals LTD and TAmiRNA GmbH enhance their collaboration

  • August 23, 2023Lepton Announced Completion of Filing for a Patent Application Extending the Usage of Its Castling Breakthrough Technologies

  • July 13, 2023Lepton Pharmaceuticals Completed the Extension Worldwide of its International Patent Covering the Breakthrough Castling Technology

  • March 20, 2023Lepton Pharmaceuticals enter into a Master Service Agreement with Reaction Biology to advance Lepton’s miRNA Castling Technology

  • July 26, 2022ERS Genomics and Lepton Pharmaceuticals LTD Enter CRISPR/Cas9 License Agreement

https://www.leptonpharma.com/wp-content/uploads/2021/04/logo_white_big-160x160.png

© 2023 Lepton Pharmaceuticals Inc.  All rights reserved
Design & Development by WCT

Our products

  • LN-Cast-01
  • LN-008 siMASP2

Our science

  • Castling Technology
  • siRNA and miRNA
  • Non-coding RNA
  • siRNA Advantages

Terms of use

  • Terms of Use
  • Copyright Info
  • Privacy Policy